American Heart Journal
Volume 155, Issue 1 , Pages 49-55 , January 2008

Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial

  • David A. Morrow, MD, MPH

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • These authors contributed equally to this work.
    • Corresponding Author InformationReprint requests: David A. Morrow, MD, MPH, is to be contacted at TIMI Study Group/Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Daniel I. Simon, MD, Division of Cardiovascular Medicine, University Hospitals Case Medical Center, 11100 Euclid Avenue Lakeside 3001, Cleveland, OH 44106.
    • ,
  • Yunmei Wang, PhD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • These authors contributed equally to this work.
    • ,
  • Kevin Croce, MD, PhD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • ,
  • Masashi Sakuma, MD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • ,
  • Marc S. Sabatine, MD, MPH

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Donald W. Reynolds Center for Clinical Cardiovascular Research, Brigham and Women's Hospital, Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Huiyun Gao, MD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • ,
  • Aruna D. Pradhan, MD

      Affiliations

    • Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA
    • ,
  • Aileen M. Healy, PhD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • ,
  • Jacki Buros, BS

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • ,
  • Carolyn H. McCabe, BS

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • ,
  • Peter Libby, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Donald W. Reynolds Center for Clinical Cardiovascular Research, Brigham and Women's Hospital, Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Eugene Braunwald, MD

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Daniel I. Simon, MD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • Corresponding Author InformationReprint requests: David A. Morrow, MD, MPH, is to be contacted at TIMI Study Group/Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Daniel I. Simon, MD, Division of Cardiovascular Medicine, University Hospitals Case Medical Center, 11100 Euclid Avenue Lakeside 3001, Cleveland, OH 44106.

Received 29 April 2007 ,Accepted 20 August 2007.

References 

  1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  2. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 2003;108:250–252
  3. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850
  4. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113:2278–2284
  5. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60:540–551
  6. Nacken W, Roth J, Sorg C, et al. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60:569–580
  7. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  8. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363–373
  9. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902
  10. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  11. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049–1052
  12. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718–1720
  13. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488
  14. Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260–4268
  15. Liao H, Wu J, Kuhn E, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004;50:3792–3803
  16. Newton RA, Thiel M, Hogg N. Signaling mechanisms and the activation of leukocyte integrins. J Leukoc Biol. 1997;61:422–426
  17. Eue I, Langer C, Eckardstein A, et al. Myeloid related protein (MRP) 14 expressing monocytes infiltrate atherosclerotic lesions of ApoE null mice. Atherosclerosis. 2000;151:593–597
  18. Bouma G, Lam-Tse WK, Wierenga-Wolf AF, et al. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes. 2004;53:1979–1986
  19. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901
  20. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445
  21. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:1425–1433
  22. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122:379–391

 The PROVE IT-TIMI 22 trial was supported by Bristol-Myers Squibb, Princeton, NJ. Drs Morrow and Sabatine are supported in part by National Institutes of Health grant U01 HL083-1341. This work was also supported in part by grants from the National Institutes of Health (HL57506 and HL60942 to Dr Simon). Dr Pradhan is supported by funding from the National Institutes of Health (HL082740). Dr Libby is supported by research funds from the Leducq Foundation (Paris, France), the Doris Duke Foundation (New York, NY), and the Donald W. Reynolds Foundation (Las Vegas, NV).

PII: S0002-8703(07)00704-1

doi: 10.1016/j.ahj.2007.08.018

American Heart Journal
Volume 155, Issue 1 , Pages 49-55 , January 2008

Article Tools

* Image Usage & Resolution